Multicenter prospective observational study to identify plasm beta cell-specific peptides

JRCT ID: jRCT1030220111

Registered date:04/06/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Type 1 diabetes
• Date of first enrollment: 21/06/2022
• Target sample size: 300
• Study type: Observational

Outcome(s)

• Primary Outcome: Identification of plasma peptides specific to patients with type 1 diabetes and patients with type 1 diabetes induced by immune checkpoint inhibitors.
• Secondary Outcome: Comparison of plasma peptides at study entry and 12-24 weeks after entry in patients with type 1 diabetes and type 1 diabetes induced by immune checkpoint inhibitors.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: More than 18 years old patients with a diagnosis of type 1 diabetes and type 1 diabetes caused by immune checkpoint inhibitors from the date of approval by the hospital director to March 31, 2025, have been started treatment at the Department of Endocrinology and Metabolism, Kitasato University Hospital or the Department of Endocrinology and Metabolism, Kitasato University Medical Center, understand the purpose of this study and are given consent. More than 18 years old normal glucose-tolerant subjects (volunteers) understand the purpose of the study and are given their consent. Volunteers will be recruited by posting posters on the bulletin board in the School of Medicine.
• Exclude criteria: None

Related Information

• Primary Sponsor: Miyatsuka Takeshi